<DOC>
	<DOCNO>NCT01777763</DOCNO>
	<brief_summary>The purpose study collect pharmacokinetic ( PK ) information relate well posaconazole tablet distribute body determine safety new formulation . The study consist Phase 1B study include participant neutropenia undergo chemotherapy acute myelogenous leukemia ( AML ) myelodysplasia ( MDS ) Phase 3 study include participant undergo chemotherapy AML MDS participant recipient allogeneic hematopoietic stem cell transplant ( HSCT ) .</brief_summary>
	<brief_title>Pharmacokinetics Safety Posaconazole Tablet Participants High Risk Invasive Fungal Infections ( MK-5592-065/P05615 )</brief_title>
	<detailed_description>Participants blood disease cancer affect infection-fighting white blood cell undergone hematopoietic stem cell transplant ( HSCT ) receive immunosuppressive therapy risk graft-vs-host disease ( GVHD ) eligible study . These blood disease treatment weaken immune system may put individual high risk serious fungal infection internal organ blood ( invasive fungal infection ) . As infection hard detect early life-threatening , many physician believe individual diagnose disease receive antifungal therapy try low risk get type infection . Enrollment study take place several stage ( part ) . The determination part participant base part open site time enrollment .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Posaconazole</mesh_term>
	<criteria>Body weight &gt; 34 kg ( 75 lb ) race/ethnicity Able swallow oral tablet whole Anticipated ( likely develop within 35 day ) document neutropenia due chemotherapy , chemotherapy new diagnosis acute myelogenous leukemia ( AML ) , AML first relapse ; myelodysplastic syndrome ( MDS ) transformation AML ; allogeneic hematopoietic stem cell transplant ( HSCT ) participant preengraftment period postengraftment period receive immunosuppressive therapy graft versus host disease Female must pregnant , must intend become pregnant study , must nurse History hypersensitivity azoles Moderate severe liver dysfunction define aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) level great three time upper limit normal ( ULN ) , AND total bilirubin level great two time ULN Electrocardiogram ( ECG ) correct QTc interval great 500 msec Posaconazole within 10 day study enrollment Receipt systemic antifungal therapy within 30 day study enrollment reason antifungal prophylaxis Evidence know suspect invasive systemic fungal infection baseline Known suspect history Gilbert 's disease Creatinine clearance level 30 mL/min</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>